Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis | Zendy

Yoav Barnea | Zendy; Anat Lerner | Zendy; Asaf Aizic | Zendy; Shiri NavonVenezia | Zendy; Eleanor Rachi | Zendy; Michael W. Dunne | Zendy; Sailaja Puttagunta | Zendy; Yehuda Carmeli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis

Author(s) -

Yoav Barnea,

Anat Lerner,

Asaf Aizic,

Shiri NavonVenezia,

Eleanor Rachi,

Michael W. Dunne,

Sailaja Puttagunta,

Yehuda Carmeli

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv357

Subject(s) - dalbavancin , medicine , vancomycin , staphylococcus aureus , osteomyelitis , saline , antibiotics , surgery , anesthesia , microbiology and biotechnology , biology , bacteria , genetics

Dalbavancin, a semi-synthetic lipoglycopeptide, is characterized by a long plasma half-life, which allows weekly dosing. Dalbavancin may be a good treatment option for patients with deep sternal wound infections owing to its improved pharmacokinetic profile and antibacterial activity compared with currently used antibiotics. Here we evaluated the efficacy of 7 or 14 days of treatment with dalbavancin, compared with vancomycin and with saline, in reducing sternal bone MRSA counts in a rat Staphylococcus aureus deep sternal wound infection model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research